Global Endothelin Antagonists Therapeutics Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Endothelin Antagonists Therapeutics Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Endothelin are the type of therapeutics that inhibits the action of endothelin and is thus effective for treating pulmonary arterial hypertension. This receptor, which plays a major role in regulating vascular tone, is found between the lumen and underlying media of the pulmonary vasculature. For patients suffering from the pulmonary hypertension, the body secrete high amount of endothelin that causes the blood vessels to be constricted and increase in the BP in the pulmonary arteries.
Endothelin Antagonists Therapeutics report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Endothelin Antagonists Therapeutics market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Cardiovascular Diseases and Scleroderma are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Endothelin Antagonists Therapeutics industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Endothelin Antagonists Therapeutics key manufacturers include Gilead Sciences, Inc, Sun Pharmaceutical Industries Ltd, Lupin, Zydus Group, Endo International plc, Mylan NV, Teva Pharmaceutical Industries Ltd, Sigmapharm Laboratories , LLC and Alembic Pharmaceuticals Limited, etc. Gilead Sciences, Inc, Sun Pharmaceutical Industries Ltd, Lupin are top 3 players and held % sales share in total in 2022.
Endothelin Antagonists Therapeutics can be divided into Oral and Parenteral, etc. Oral is the mainstream product in the market, accounting for % sales share globally in 2022.
Endothelin Antagonists Therapeutics is widely used in various fields, such as Cardiovascular Diseases, Scleroderma and Other,, etc. Cardiovascular Diseases provides greatest supports to the Endothelin Antagonists Therapeutics industry development. In 2022, global % sales of Endothelin Antagonists Therapeutics went into Cardiovascular Diseases filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Endothelin Antagonists Therapeutics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Gilead Sciences, Inc
Sun Pharmaceutical Industries Ltd
Lupin
Zydus Group
Endo International plc
Mylan NV
Teva Pharmaceutical Industries Ltd
Sigmapharm Laboratories , LLC
Alembic Pharmaceuticals Limited
Hikma Pharmaceuticals PLC
Amneal Pharmaceuticals LLC
AstraZeneca
Johnsons & Johnsons Private limited
GSK Plc
Segment by Type
Oral
Parenteral
Cardiovascular Diseases
Scleroderma
Other
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Endothelin Antagonists Therapeutics market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Endothelin Antagonists Therapeutics, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Endothelin Antagonists Therapeutics industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Endothelin Antagonists Therapeutics in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Endothelin Antagonists Therapeutics introduction, etc. Endothelin Antagonists Therapeutics Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Endothelin Antagonists Therapeutics market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Endothelin Antagonists Therapeutics report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Endothelin Antagonists Therapeutics market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Cardiovascular Diseases and Scleroderma are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Endothelin Antagonists Therapeutics industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Endothelin Antagonists Therapeutics key manufacturers include Gilead Sciences, Inc, Sun Pharmaceutical Industries Ltd, Lupin, Zydus Group, Endo International plc, Mylan NV, Teva Pharmaceutical Industries Ltd, Sigmapharm Laboratories , LLC and Alembic Pharmaceuticals Limited, etc. Gilead Sciences, Inc, Sun Pharmaceutical Industries Ltd, Lupin are top 3 players and held % sales share in total in 2022.
Endothelin Antagonists Therapeutics can be divided into Oral and Parenteral, etc. Oral is the mainstream product in the market, accounting for % sales share globally in 2022.
Endothelin Antagonists Therapeutics is widely used in various fields, such as Cardiovascular Diseases, Scleroderma and Other,, etc. Cardiovascular Diseases provides greatest supports to the Endothelin Antagonists Therapeutics industry development. In 2022, global % sales of Endothelin Antagonists Therapeutics went into Cardiovascular Diseases filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Endothelin Antagonists Therapeutics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Gilead Sciences, Inc
Sun Pharmaceutical Industries Ltd
Lupin
Zydus Group
Endo International plc
Mylan NV
Teva Pharmaceutical Industries Ltd
Sigmapharm Laboratories , LLC
Alembic Pharmaceuticals Limited
Hikma Pharmaceuticals PLC
Amneal Pharmaceuticals LLC
AstraZeneca
Johnsons & Johnsons Private limited
GSK Plc
Segment by Type
Oral
Parenteral
Segment by Application
Cardiovascular Diseases
Scleroderma
Other
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Endothelin Antagonists Therapeutics market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Endothelin Antagonists Therapeutics, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Endothelin Antagonists Therapeutics industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Endothelin Antagonists Therapeutics in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Endothelin Antagonists Therapeutics introduction, etc. Endothelin Antagonists Therapeutics Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Endothelin Antagonists Therapeutics market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices